Deuterium Capital Management LLC Purchases New Position in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)

Deuterium Capital Management LLC acquired a new position in shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 12,572 shares of the biotechnology company’s stock, valued at approximately $531,000. Cerevel Therapeutics accounts for 1.0% of Deuterium Capital Management LLC’s investment portfolio, making the stock its 19th biggest position.

A number of other institutional investors and hedge funds have also bought and sold shares of CERE. Pacific Capital Wealth Advisors Inc. purchased a new stake in shares of Cerevel Therapeutics in the 4th quarter worth approximately $71,000. Centaurus Financial Inc. bought a new stake in Cerevel Therapeutics during the 4th quarter valued at $119,000. GAM Holding AG purchased a new position in shares of Cerevel Therapeutics in the 4th quarter valued at $212,000. Virtu Financial LLC bought a new position in shares of Cerevel Therapeutics in the 4th quarter worth $246,000. Finally, Trexquant Investment LP bought a new position in shares of Cerevel Therapeutics in the 3rd quarter worth $314,000. 87.73% of the stock is owned by institutional investors.

Cerevel Therapeutics Stock Down 1.8 %

NASDAQ:CERE traded down $0.74 during midday trading on Friday, reaching $40.31. 976,148 shares of the stock traded hands, compared to its average volume of 1,542,042. The stock has a market capitalization of $7.34 billion, a PE ratio of -14.77 and a beta of 1.40. Cerevel Therapeutics Holdings, Inc. has a 12-month low of $19.59 and a 12-month high of $43.59. The company has a debt-to-equity ratio of 0.60, a quick ratio of 10.22 and a current ratio of 10.22. The business has a 50-day moving average of $41.20 and a two-hundred day moving average of $41.78.

Cerevel Therapeutics (NASDAQ:CERE) last announced its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.12). On average, equities analysts forecast that Cerevel Therapeutics Holdings, Inc. will post -2.59 earnings per share for the current fiscal year.

Insider Transactions at Cerevel Therapeutics

In other Cerevel Therapeutics news, Director N Anthony Coles sold 50,000 shares of Cerevel Therapeutics stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $42.10, for a total transaction of $2,105,000.00. Following the completion of the sale, the director now owns 15,638 shares of the company’s stock, valued at approximately $658,359.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 5.10% of the company’s stock.

Cerevel Therapeutics Company Profile

Cerevel Therapeutics Holdings, Inc, a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model.